Chemicals - Specialty
Compare Stocks
2 / 10Stock Comparison
CBT vs LIN
Revenue, margins, valuation, and 5-year total return — side by side.
Chemicals - Specialty
CBT vs LIN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Chemicals - Specialty | Chemicals - Specialty |
| Market Cap | $4.12B | $231.88B |
| Revenue (TTM) | $3.61B | $34.66B |
| Net Income (TTM) | $311M | $7.13B |
| Gross Margin | 25.4% | 46.0% |
| Operating Margin | 16.5% | 28.8% |
| Forward P/E | 13.2x | 28.1x |
| Total Debt | $1.22B | $26.99B |
| Cash & Equiv. | $258M | $5.06B |
CBT vs LIN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Cabot Corporation (CBT) | 100 | 230.7 | +130.7% |
| Linde plc (LIN) | 100 | 248.0 | +148.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CBT vs LIN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CBT is the clearest fit if your priority is defensive.
- Beta 0.78, yield 2.2%, current ratio 1.61x
- Lower P/E (13.2x vs 28.1x)
- 2.2% yield, 4-year raise streak, vs LIN's 1.2%
LIN carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 6 yrs, beta 0.24, yield 1.2%
- Rev growth 3.0%, EPS growth 7.1%, 3Y rev CAGR 0.6%
- 379.1% 10Y total return vs CBT's 110.5%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 3.0% revenue growth vs CBT's -7.0% | |
| Value | Lower P/E (13.2x vs 28.1x) | |
| Quality / Margins | 20.6% margin vs CBT's 8.6% | |
| Stability / Safety | Beta 0.24 vs CBT's 0.78, lower leverage | |
| Dividends | 2.2% yield, 4-year raise streak, vs LIN's 1.2% | |
| Momentum (1Y) | +11.9% vs CBT's +4.2% | |
| Efficiency (ROA) | 8.3% ROA vs CBT's 8.2%, ROIC 11.3% vs 17.4% |
CBT vs LIN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
CBT vs LIN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
LIN leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LIN is the larger business by revenue, generating $34.7B annually — 9.6x CBT's $3.6B. LIN is the more profitable business, keeping 20.6% of every revenue dollar as net income compared to CBT's 8.6%. On growth, LIN holds the edge at +8.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $3.6B | $34.7B |
| EBITDAEarnings before interest/tax | $753M | $12.1B |
| Net IncomeAfter-tax profit | $311M | $7.1B |
| Free Cash FlowCash after capex | $401M | $5.1B |
| Gross MarginGross profit ÷ Revenue | +25.4% | +46.0% |
| Operating MarginEBIT ÷ Revenue | +16.5% | +28.8% |
| Net MarginNet income ÷ Revenue | +8.6% | +20.6% |
| FCF MarginFCF ÷ Revenue | +11.1% | +14.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | -11.1% | +8.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -17.4% | +13.4% |
Valuation Metrics
CBT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
At 13.1x trailing earnings, CBT trades at a 62% valuation discount to LIN's 34.3x P/E. On an enterprise value basis, CBT's 6.6x EV/EBITDA is more attractive than LIN's 20.0x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $4.1B | $231.9B |
| Enterprise ValueMkt cap + debt − cash | $5.1B | $253.8B |
| Trailing P/EPrice ÷ TTM EPS | 13.11x | 34.30x |
| Forward P/EPrice ÷ next-FY EPS est. | 13.23x | 28.12x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.35x |
| EV / EBITDAEnterprise value multiple | 6.55x | 19.99x |
| Price / SalesMarket cap ÷ Revenue | 1.11x | 6.82x |
| Price / BookPrice ÷ Book value/share | 2.51x | 5.90x |
| Price / FCFMarket cap ÷ FCF | 10.54x | 45.56x |
Profitability & Efficiency
CBT leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
CBT delivers a 18.5% return on equity — every $100 of shareholder capital generates $19 in annual profit, vs $18 for LIN. LIN carries lower financial leverage with a 0.68x debt-to-equity ratio, signaling a more conservative balance sheet compared to CBT's 0.71x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +18.5% | +17.8% |
| ROA (TTM)Return on assets | +8.2% | +8.3% |
| ROICReturn on invested capital | +17.4% | +11.3% |
| ROCEReturn on capital employed | +21.3% | +13.0% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 6 |
| Debt / EquityFinancial leverage | 0.71x | 0.68x |
| Net DebtTotal debt minus cash | $957M | $21.9B |
| Cash & Equiv.Liquid assets | $258M | $5.1B |
| Total DebtShort + long-term debt | $1.2B | $27.0B |
| Interest CoverageEBIT ÷ Interest expense | 8.09x | 34.52x |
Total Returns (Dividends Reinvested)
LIN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIN five years ago would be worth $18,055 today (with dividends reinvested), compared to $14,278 for CBT. Over the past 12 months, LIN leads with a +11.9% total return vs CBT's +4.2%. The 3-year compound annual growth rate (CAGR) favors LIN at 12.2% vs CBT's 5.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | +18.4% | +17.0% |
| 1-Year ReturnPast 12 months | +4.2% | +11.9% |
| 3-Year ReturnCumulative with dividends | +17.8% | +41.2% |
| 5-Year ReturnCumulative with dividends | +42.8% | +80.6% |
| 10-Year ReturnCumulative with dividends | +110.5% | +379.1% |
| CAGR (3Y)Annualised 3-year return | +5.6% | +12.2% |
Risk & Volatility
LIN leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
LIN is the less volatile stock with a 0.24 beta — it tends to amplify market swings less than CBT's 0.78 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.78x | 0.24x |
| 52-Week HighHighest price in past year | $83.71 | $521.28 |
| 52-Week LowLowest price in past year | $58.33 | $387.78 |
| % of 52W HighCurrent price vs 52-week peak | +94.3% | +96.0% |
| RSI (14)Momentum oscillator 0–100 | 53.3 | 45.6 |
| Avg Volume (50D)Average daily shares traded | 363K | 2.3M |
Analyst Outlook
Evenly matched — CBT and LIN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Wall Street rates CBT as "Buy" and LIN as "Buy". Consensus price targets imply 7.9% upside for LIN (target: $540) vs -1.2% for CBT (target: $78). For income investors, CBT offers the higher dividend yield at 2.24% vs LIN's 1.20%.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $78.00 | $539.71 |
| # AnalystsCovering analysts | 15 | 28 |
| Dividend YieldAnnual dividend ÷ price | +2.2% | +1.2% |
| Dividend StreakConsecutive years of raises | 4 | 6 |
| Dividend / ShareAnnual DPS | $1.77 | $6.00 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.1% | +2.0% |
LIN leads in 3 of 6 categories (Income & Cash Flow, Total Returns). CBT leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.
CBT vs LIN: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is CBT or LIN a better buy right now?
For growth investors, Linde plc (LIN) is the stronger pick with 3.
0% revenue growth year-over-year, versus -7. 0% for Cabot Corporation (CBT). Cabot Corporation (CBT) offers the better valuation at 13. 1x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Cabot Corporation (CBT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CBT or LIN?
On trailing P/E, Cabot Corporation (CBT) is the cheapest at 13.
1x versus Linde plc at 34. 3x. On forward P/E, Cabot Corporation is actually cheaper at 13. 2x.
03Which is the better long-term investment — CBT or LIN?
Over the past 5 years, Linde plc (LIN) delivered a total return of +80.
6%, compared to +42. 8% for Cabot Corporation (CBT). Over 10 years, the gap is even starker: LIN returned +376. 9% versus CBT's +115. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CBT or LIN?
By beta (market sensitivity over 5 years), Linde plc (LIN) is the lower-risk stock at 0.
24β versus Cabot Corporation's 0. 78β — meaning CBT is approximately 226% more volatile than LIN relative to the S&P 500. On balance sheet safety, Linde plc (LIN) carries a lower debt/equity ratio of 68% versus 71% for Cabot Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — CBT or LIN?
By revenue growth (latest reported year), Linde plc (LIN) is pulling ahead at 3.
0% versus -7. 0% for Cabot Corporation (CBT). On earnings-per-share growth, the picture is similar: Linde plc grew EPS 7. 1% year-over-year, compared to -10. 4% for Cabot Corporation. Over a 3-year CAGR, LIN leads at 0. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CBT or LIN?
Linde plc (LIN) is the more profitable company, earning 20.
3% net margin versus 8. 9% for Cabot Corporation — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIN leads at 26. 3% versus 16. 7% for CBT. At the gross margin level — before operating expenses — LIN leads at 43. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CBT or LIN more undervalued right now?
On forward earnings alone, Cabot Corporation (CBT) trades at 13.
2x forward P/E versus 28. 1x for Linde plc — 14. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for LIN: 7. 9% to $539. 71.
08Which pays a better dividend — CBT or LIN?
All stocks in this comparison pay dividends.
Cabot Corporation (CBT) offers the highest yield at 2. 2%, versus 1. 2% for Linde plc (LIN).
09Is CBT or LIN better for a retirement portfolio?
For long-horizon retirement investors, Linde plc (LIN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
24), 1. 2% yield, +376. 9% 10Y return). Both have compounded well over 10 years (LIN: +376. 9%, CBT: +115. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CBT and LIN?
Both stocks operate in the Basic Materials sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CBT is a small-cap deep-value stock; LIN is a large-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.